...Thank you, Stacey, and good morning. We appreciate you joining us today for a review of our third quarter 2020 financial results and business update. As Stacey mentioned, joining me on the call today are Will Brown, our Chief Financial Officer; Scot Roberts, our Chief Scientific Officer; and Scott Harris, our Chief Medical Officer. After our prepared remarks, we will hold a Q&A session. 2020 continues to be a transformational year for Altimmune and our shareholders. In particular, the third quarter has been an exceptionally busy time as we progressed 5 novel investigational candidates in clinical development. Never in our history have we had so much opportunity to build value and so many promising shots on goal that are advancing towards clear inflection points over the next 6 to 12 months. I'm especially proud of our accomplishments as they relate to our COVID-19 candidates, as we have achieved so much in a compressed time frame. At the outset of the year, as the pandemic swept around...
